Equities analysts predict that Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) will report earnings of ($0.42) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Aldeyra Therapeutics’ earnings, with estimates ranging from ($0.50) to ($0.36). Aldeyra Therapeutics reported earnings per share of ($0.38) during the same quarter last year, which would suggest a negative year-over-year growth rate of 10.5%. The company is scheduled to issue its next earnings report on Monday, November 13th.
According to Zacks, analysts expect that Aldeyra Therapeutics will report full year earnings of ($1.67) per share for the current fiscal year, with EPS estimates ranging from ($2.12) to ($1.43). For the next fiscal year, analysts forecast that the business will post earnings of ($1.75) per share, with EPS estimates ranging from ($2.49) to ($1.24). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that follow Aldeyra Therapeutics.
Aldeyra Therapeutics (NASDAQ:ALDX) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.35) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.02.
Several equities analysts recently issued reports on ALDX shares. Zacks Investment Research upgraded Aldeyra Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research report on Thursday, August 10th. Canaccord Genuity restated a “buy” rating and set a $27.00 price target (up from $12.00) on shares of Aldeyra Therapeutics in a research report on Wednesday, September 13th. Cowen and Company restated an “outperform” rating and set a $14.00 price target (up from $9.00) on shares of Aldeyra Therapeutics in a research report on Thursday, September 14th. ValuEngine upgraded Aldeyra Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 12th. Finally, HC Wainwright set a $18.00 price target on Aldeyra Therapeutics and gave the stock a “buy” rating in a research report on Thursday, June 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $15.95.
Shares of Aldeyra Therapeutics (NASDAQ ALDX) traded down 5.16% during mid-day trading on Thursday, reaching $7.35. The company had a trading volume of 397,478 shares. The stock has a 50 day moving average price of $6.08 and a 200 day moving average price of $5.01. Aldeyra Therapeutics has a 12-month low of $3.80 and a 12-month high of $11.90. The firm’s market capitalization is $136.71 million.
In other Aldeyra Therapeutics news, major shareholder Life Sciences Maste Perceptive acquired 200,000 shares of the business’s stock in a transaction dated Tuesday, September 19th. The shares were purchased at an average cost of $7.25 per share, for a total transaction of $1,450,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 28.40% of the stock is currently owned by company insiders.
Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its position in shares of Aldeyra Therapeutics by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock worth $1,431,000 after buying an additional 9,407 shares during the last quarter. Virtu KCG Holdings LLC bought a new stake in shares of Aldeyra Therapeutics in the 2nd quarter worth approximately $104,000. Renaissance Technologies LLC bought a new stake in shares of Aldeyra Therapeutics in the 1st quarter worth approximately $132,000. Hikari Power Ltd grew its position in shares of Aldeyra Therapeutics by 186.4% in the 2nd quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock worth $507,000 after buying an additional 70,196 shares during the last quarter. Finally, Sabby Management LLC bought a new stake in shares of Aldeyra Therapeutics in the 1st quarter worth approximately $898,000. Hedge funds and other institutional investors own 40.06% of the company’s stock.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.